<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308865</url>
  </required_header>
  <id_info>
    <org_study_id>2013_70</org_study_id>
    <secondary_id>2014-A00514-43</secondary_id>
    <nct_id>NCT02308865</nct_id>
  </id_info>
  <brief_title>Early Palliative Care in Metastatic Lung Cancer in Northern France</brief_title>
  <acronym>IMPAQ</acronym>
  <official_title>Impact of Early Palliative Care on Quality of Life and Survival of Patients With Non-small-cell Metastatic Lung Cancer in Northern France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SANTELYS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, prospective, controlled, open-label, randomized, two parallel arms comparing
      early Palliative care versus Standard care in patients with non-small-cell metastatic lung
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      144 patients will be included; 72 per arm.

        -  &quot;Standard&quot; Control arm: patient supported by the onco-respiratory service.

        -  Intervention arm: patients benefit from early palliative care in addition to standard
           onco-pneumologic care.

      The main criterion of judgment is the TOI score measured at 12 weeks.

      FACTL questionnaires, HADS and PHQ-9 will be filled out before randomization , at 12 weeks
      and 21 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2014</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>quality of life is measured at 12 weeks by the TOI score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SURVIVAL</measure>
    <time_frame>from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVENTS</measure>
    <time_frame>14 days before deaths</time_frame>
    <description>presence of any of the following: chemotherapy, use of resuscitation or no treatment limiting decision 14 days before deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QUALITY OF LIFE</measure>
    <time_frame>12 and 21 weeks</time_frame>
    <description>quality of life is measured by the score TOI at 12 weeks and by the Echelle SCNS - SF34 scale, FACTL, PHQ-9 and HADS questionnaires at 12 and 21 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>multi disciplinary palliative care monthly consultations</intervention_name>
    <description>multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory</description>
    <arm_group_label>intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being diagnosed with non-small cell lung cancer

               -  Proven histologically

               -  Metastatic proven imaging (MRI, CT Scanner, PET scan)

               -  Stage IV (any T, any N, M1)

          -  prior to secondary chemotherapy treatment.

          -  Age&gt; 18 years

          -  PS ≤2

          -  Patient able to understand the nature, purpose and methodology of the study

          -  signed Informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Patient already supported by palliative care

          -  Patient with an activating EGFR mutation or EML4-ALK rearrangement or ROS1 gene
             translocation

          -  Patient under trusteeship / guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Licia Touzet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Licia Touzet, MD</last_name>
    <email>licia.touzet@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LICIA TOUZET</last_name>
      <email>licia.touzet@CHRU-LILLE.FR</email>
    </contact>
    <contact_backup>
      <last_name>XAVIER DHALLUIN</last_name>
      <email>Xavier.DHALLUIN@CHRU-LILLE.FR</email>
    </contact_backup>
    <investigator>
      <last_name>Licia Touzet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Dhalluin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.</citation>
    <PMID>20818875</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early palliative care</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

